期刊文献+

中国内地2型糖尿病合并高血压患者微量白蛋白尿检出率调查 被引量:18

A survey of microalbuminuria prevalence in hypertensive type 2 diabetic patients in China's Mainland
原文传递
导出
摘要 目的调查内分泌科及心内科门诊中糖尿病合并高血压患者微量白蛋白尿(MA)检出率。方法多中心连续收集2型糖尿病合并高血压患者共2473例,采用统一调查表记录患者糖尿病、高血压控制情况及相关并发症,测量血压。采用 Micral-Ⅱ试纸半定量比色法筛查尿微量白蛋白。结果 2型糖尿病合并高血压患者 MA 的检出率为42.9%,大量白蛋白尿检出率17.0%。多因素回归分析显示,患者年龄、收缩压水平、空腹血糖水平以及 BMI 与糖尿病合并高血压患者 MA 的发生独立相关;除上述因素外,尚有糖尿病病程、应用利尿剂与大量白蛋白尿的发生独立相关。结论在2型糖尿病合并高血压患者中 MA 检出率极高,MA 筛查及强力降压治疗甚为重要。 Objective To determine the prevalence and risk factors of microalbuminuria(MA) in diabetic patients with hypertension in China's Mainland. Methods This cross-sectional study involved 2473 patients enrolled from 42 diabetic and cardiac outpatient clinics. An immunospecific dipstick Micral Test Ⅱ was used for MA screening and Nephur7 urinary strip for macroalbuminuria. In addition, blood pressure levels were recorded and questionnaire forms were filled out. Chi square and logistic regression analyses were used for statistical analyses. Results In the study population the prevalence of MA in hypertensive type 2 diabetic patients was 42.9% and that of macroalbuminuria was 17.0%. Logistic regression analysis showed that age, BMI and systolic blood pressure were independently associated with the occurrence of MA, while the duration of type 2 diabetic and diuretics used were independently associated with the occurrence of macroalbuminuria. Conclusions It is shown that there is a high prevalence of MA in hypertensive diabetic patients. Screening of MA and lowering of blood pressure should be the important measures for lowering its occurrence.
出处 《中华内科杂志》 CAS CSCD 北大核心 2007年第3期184-188,共5页 Chinese Journal of Internal Medicine
关键词 糖尿病 高血压 微量白蛋白尿 Diabetes mellitus Hypertension Microalbuminuria
  • 相关文献

参考文献18

  • 1Lebovitz HE, Wiegmann TB, Cnaan A, et al. Renal protective effects of enalapril in hypertensive NIDDM: role of baseline albuminuria. Kidney Int Suppl, 1994,45 :S150-155.
  • 2Stamler J, Vaccaro O, Neaton JD, et al. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care, 1993,16:434-444.
  • 3Molitch ME, DeFronzo RA, Franz MJ, et al. Diabetic Nephropathy. Diabetes Care,2003,26 Suppl 1 : S94-S98.
  • 4Pan CY, Du J, Hou XX. Comparison of the three methods for urinary albumin determination in Chinese diabetic patients. 18th International Diabetes Federation Congress. Diabetes Metab,2003,29:4S35.
  • 5King H, Aubert BE, Herman WH. Global burden of diabetes,1995-2025: prevalence, numerical estimates, and projections.Diabetes Care, 1998, 21:1414-1431.
  • 6Epstein M, Sowers JR. Diabetes mellitus and hypertension.Hypertension, 1992, 19:403-418.
  • 7Collins AJ, Kasiske B, Herzog C, et al. Excerpts from the United States Renal Data System 2004 annual data report: atlas of endstage renal disease in the United States. Am J Kidney Dis, 2005,45(1 Suppl 1) :A5-7.
  • 8Park HY, Schumock GT, Pickard AS, et al. A structured review of the relationship between microalbuminuria and cardiovascular events in patients with diabetes mellitus and hypertension.Pharmacotherapy, 2003, 23: 1611-1616.
  • 9Effects of ramipril on cardiovascular and microvescular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet, 2000, 355:253-259.
  • 10Parring HH, Lehnert H, Brochner-Mortensen J, et al. The erect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med, 2001,345:870-878.

共引文献56

同被引文献171

引证文献18

二级引证文献194

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部